You searched for Antibody candidate - Page 46 of 69

News and Trends 23 Oct 2024

RNA editing in humans: the race begins with first successful trial

…received a single 200 mg dose of WVE-006. The candidate is designed to correct the single base in the mutant SERPINA1 mRNA by reverting the mutant A (adenosine) to an…

October 23, 2024 - 6 minutesmins - By Roohi Mariam Peter

Best in Biotech 11 Jan 2021

The 21 European Biotech Companies To Watch in 2021

…In 2020, results of a phase III trial showed that its lead candidate efgartigimod improved motor symptoms of patients living with myasthenia gravis, a rare, chronic autoimmune disease. The company…

January 11, 2021 - 11 minutesmins - By Larissa Warneck-Silvestrin

In Depth 22 May 2024

The undruggable cancer target: KRAS inhibitors move ahead in the clinic

…a report by Cancer.Net. KRAS inhibitors battle it out in the clinical arena KRAS inhibitors head-to-head: adagrasib versus sotorasib Like BridgeBio, other biopharmas are ushering their candidates towards the clinic….

May 22, 2024 - 8 minutesmins - By Roohi Mariam Peter

News and Trends 14 Aug 2024

CAR-T drugs and parkinsonism: a cause for concern?

…a clinical trial halt for a CAR-T candidate. Belgian pharmaceutical Galapagos paused the enrollment of patients in a phase 1/2 trial that began last year. The study was designed to…

August 14, 2024 - 3 minutesmins - By Roohi Mariam Peter

redhill biopharma israel gastrointestinal crohns cancer pancreatic rhb 104

News and Trends 3 Mar 2016

This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

…projects. One candidate (RHB-104) is in a phase II trial for Multiple Sclerosis, and another potential indication is Rheumatoid Arthritis. And there are several other advanced projects in the pipeline……

March 3, 2016 - 3 minutesmins - By Denise Neves Gameiro

In Depth 13 Mar 2024

From LSD to healing minds: Where are we standing in psychedelic drug development?

…of the quality of the candidate itself to recoup their investment,” explained Qi. Qi describes the second phase as when companies such as Cybin were using deuterated psychedelic molecules, the…

March 13, 2024 - 13 minutesmins - By Jules Adam

News and Trends 11 Dec 2017

Could this British Biotech’s Drug Help to Bring Down COPD Hospitalizations?

…numbers of people smoking, rising air pollution and an aging population. Mereo could be onto a winner, with the candidate potentially filling a gap in the market, with no approved…

December 11, 2017 - 3 minutesmins - By Alex Dale

News and Trends 29 Oct 2020

Universal Flu Vaccines Yield Second Clinical Failure This Year

…This was BiondVax’s only clinical candidate and investors reacted poorly, sending the stock into free fall. Back in June, BiondVax reported that the vaccine had shown promise against flu by…

October 29, 2020 - 5 minutesmins - By Jonathan Smith

News and Trends 2 Nov 2017

Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes

Two Swedish biotechs, Betagenon and Baltic Bio, have announced promising preliminary Phase IIa results for their Type 2 Diabetes candidate. Betagenon develops therapies for chronic energy balance disorders and has…

November 2, 2017 - 2 minutesmins - By Alex Dale

In Depth 4 Oct 2023

CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off?

…drug (IND) status for its drug candidate AB-201, a CAR-NK therapy for the treatment of solid tumors. AB-201 became the first CAR-NK therapy candidate to tend to HER2-positive cancer indications,…

October 4, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 5 Feb 2018

New Antiviral for RSV Lung Infections Shows Promise in Phase IIa

ReViral’s candidate RV521 showed its potential for the treatment of respiratory syncytial virus (RSV) infections by reducing viral load and mucus levels. London-based biotech ReViral discovers and develops antiviral drugs,…

February 5, 2018 - 3 minutesmins - By Alex Dale

vienna biotech valneva sanochemia aop pharma

News and Trends 12 Sep 2016

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

…that directly contribute to disease. For example, the lead candidate (ASN100) targets 6 cytotoxins produced by Staphylococcus aureus, a common cause of hospital-acquired infections. ASN100 started being evaluated in a…

September 12, 2016 - 6 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

RNA editing in humans: the race begins with first successful trial

The 21 European Biotech Companies To Watch in 2021

The undruggable cancer target: KRAS inhibitors move ahead in the clinic

CAR-T drugs and parkinsonism: a cause for concern?

This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

From LSD to healing minds: Where are we standing in psychedelic drug development?

Could this British Biotech’s Drug Help to Bring Down COPD Hospitalizations?

Universal Flu Vaccines Yield Second Clinical Failure This Year

Swedish Biotech Team Steps Up in the Fight Against Type 2 Diabetes

CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off?

New Antiviral for RSV Lung Infections Shows Promise in Phase IIa

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!